{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T02:00:01Z","timestamp":1775181601000,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006342","name":"Association Vaincre la Mucoviscidose","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006342","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Association la Pierre le bigaue"},{"name":"Fondation Groupama"},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["MCCOY19RO- Core C (Kopp)"],"award-info":[{"award-number":["MCCOY19RO- Core C (Kopp)"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002733"],"award-info":[{"award-number":["UL1TR002733"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cystic fibrosis (CF) is characterized by chronic bacterial infections and heightened inflammation. Widespread ineffective antibiotic use has led to increased isolation of drug resistant bacterial strains from respiratory samples. (R)-roscovitine (Seliciclib) is a unique drug that has many benefits in CF studies. We sought to determine roscovitine\u2019s impact on macrophage function and killing of multi-drug resistant bacteria. Human blood monocytes were isolated from CF (F508del\/F508del) and non-CF persons and derived into macrophages (MDMs). MDMs were infected with CF clinical isolates of<jats:italic>B. cenocepacia<\/jats:italic>and<jats:italic>P. aeruginosa.<\/jats:italic>MDMs were treated with (R)-roscovitine or its main hepatic metabolite (M3). Macrophage responses to infection and subsequent treatment were determined. (R)-roscovitine and M3 significantly increased killing of<jats:italic>B. cenocepacia<\/jats:italic>and<jats:italic>P. aeruginosa<\/jats:italic>in CF MDMs in a dose-dependent manner. (R)-roscovitine-mediated effects were partially dependent on CFTR and the TRPC6 channel. (R)-roscovitine-mediated killing of<jats:italic>B. cenocepacia<\/jats:italic>was enhanced by combination with the CFTR modulator tezacaftor\/ivacaftor and\/or the alternative CFTR modulator cysteamine. (R)-roscovitine also increased MDM CFTR function compared to tezacaftor\/ivacaftor treatment alone. (R)-roscovitine increases CF macrophage-mediated killing of antibiotic-resistant bacteria. (R)-roscovitine also enhances other macrophage functions including CFTR-mediated ion efflux. Effects of (R)-roscovitine are greatest when combined with CFTR modulators or cysteamine, justifying further clinical testing of (R)-roscovitine or optimized derivatives.<\/jats:p>","DOI":"10.1038\/s41598-020-78817-x","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T11:09:12Z","timestamp":1607598552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["(R)-Roscovitine and CFTR modulators enhance killing of multi-drug resistant Burkholderia cenocepacia by cystic fibrosis macrophages"],"prefix":"10.1038","volume":"10","author":[{"given":"Chandra L.","family":"Shrestha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuzhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Wisniewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"H\u00e4fner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Elie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin T.","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,10]]},"reference":[{"key":"78817_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1586\/17476348.2015.995640","volume":"9","author":"C Lopez-Causape","year":"2015","unstructured":"Lopez-Causape, C., Rojo-Molinero, E., Macia, M. D. & Oliver, A. The problems of antibiotic resistance in cystic fibrosis and solutions. Exp. Rev. Respir. Med. 9, 73\u201388 (2015).","journal-title":"Exp. Rev. Respir. Med."},{"key":"78817_CR2","doi-asserted-by":"crossref","unstructured":"Waters, V.J., Kidd, T.J., Canton, R., Ekkelenkamp, M.B., Johansen, H.K., LiPuma, J.J. et al. Reconciling antimicrobial susceptibility testing and clinical response in antimicrobial treatment of chronic cystic fibrosis lung infections. Clin. Infect. Dis. (2019).","DOI":"10.1093\/cid\/ciz364"},{"key":"78817_CR3","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1002\/ppul.24178","volume":"53","author":"SD Grosse","year":"2018","unstructured":"Grosse, S. D. et al. Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010\u20132016. Pediatr. Pulmonol. 53, 1611\u20131618 (2018).","journal-title":"Pediatr. Pulmonol."},{"key":"78817_CR4","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13023-018-0914-3","volume":"13","author":"D Sharma","year":"2018","unstructured":"Sharma, D. et al. Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States. Orphanet. J. Rare Dis. 13, 172 (2018).","journal-title":"Orphanet. J. Rare Dis."},{"key":"78817_CR5","doi-asserted-by":"crossref","unstructured":"Frost, F.J., Nazareth, D.S., Charman, S.C., Winstanley, C., Walshaw, M.J. Ivacaftor is associated with reduced lung infection by key cystic fibrosis pathogens: A cohort study using National Registry Data. Ann. Am. Thorac. Soc. (2019).","DOI":"10.1513\/AnnalsATS.201902-122OC"},{"key":"78817_CR6","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/ppul.24341","volume":"54","author":"SB Singh","year":"2019","unstructured":"Singh, S. B. et al. Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor\/ivacaftor. Pediatr. Pulmonol. 54, 1200\u20131208 (2019).","journal-title":"Pediatr. Pulmonol."},{"key":"78817_CR7","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","volume":"195","author":"KB Hisert","year":"2017","unstructured":"Hisert, K. B. et al. Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections. Am. J. Respir. Crit. Care Med. 195, 1617\u20131628 (2017).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"78817_CR8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1021\/ar0201198","volume":"36","author":"L Meijer","year":"2003","unstructured":"Meijer, L. & Raymond, E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc. Chem Res. 36, 417\u2013425 (2003).","journal-title":"Acc. Chem Res."},{"key":"78817_CR9","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1432-1033.1997.0518a.x","volume":"243","author":"WF De Azevedo","year":"1997","unstructured":"De Azevedo, W. F. et al. Inhibition of cyclin-dependent kinases by purine analogues: Crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem. 243, 518\u2013526 (1997).","journal-title":"Eur. J. Biochem."},{"key":"78817_CR10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1432-1033.1997.t01-2-00527.x","volume":"243","author":"L Meijer","year":"1997","unstructured":"Meijer, L. et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243, 527\u2013536 (1997).","journal-title":"Eur. J. Biochem."},{"key":"78817_CR11","doi-asserted-by":"crossref","unstructured":"Meijer, L., Bettayeb, K., & Galons, H. Roscovitine (CYC202, Seliciclib). in \"Monographs on Enzyme Inhibitors\" CDK Inhibitors and Their Potential as Anti-Tumor Agents, Vol. 2, Chap 9, 187\u2013226 (eds. Yue, E. & Smith, P.J.) (CRC Press, Taylor & Francis, 2006).","DOI":"10.1201\/9781420005400.ch9"},{"key":"78817_CR12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1021\/op800284k","volume":"13","author":"N Oumata","year":"2009","unstructured":"Oumata, N., Ferandin, Y., Meijer, L. & Galons, H. Practical synthesis of roscovitine and CR8. Organ. Process Res Dev. 13, 641\u2013644 (2009).","journal-title":"Organ. Process Res Dev."},{"key":"78817_CR13","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1159\/000444256","volume":"8","author":"L Meijer","year":"2016","unstructured":"Meijer, L. et al. Modulating innate and adaptive immunity by (R)-roscovitine: Potential therapeutic opportunity in cystic fibrosis. J. Innate Immun. 8, 330\u2013349 (2016).","journal-title":"J. Innate Immun."},{"key":"78817_CR14","doi-asserted-by":"publisher","first-page":"E6486","DOI":"10.1073\/pnas.1518966112","volume":"112","author":"V Riazanski","year":"2015","unstructured":"Riazanski, V. et al. TRPC6 channel translocation into phagosomal membrane augments phagosomal function. Proc Natl Acad Sci U S A. 112, E6486\u2013E6495 (2015).","journal-title":"Proc Natl Acad Sci U S A."},{"key":"78817_CR15","doi-asserted-by":"publisher","first-page":"4831","DOI":"10.1111\/bph.12859","volume":"171","author":"C Norez","year":"2014","unstructured":"Norez, C. et al. Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanism. Br. J. Pharmacol. 171, 4831\u20134849 (2014).","journal-title":"Br. J. Pharmacol."},{"key":"78817_CR16","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02649751?term=roscovitine&rank=1."},{"key":"78817_CR17","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/cmdc.201800021","volume":"13","author":"S Hafner","year":"2018","unstructured":"Hafner, S. et al. A (+)-larixol congener with high affinity and subtype selectivity toward TRPC6. ChemMedChem 13, 1028\u20131035 (2018).","journal-title":"ChemMedChem"},{"key":"78817_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.bbrc.2012.06.066","volume":"424","author":"BT Kopp","year":"2012","unstructured":"Kopp, B. T. et al. Exaggerated inflammatory responses mediated by Burkholderia cenocepacia in human macrophages derived from cystic fibrosis patients. Biochem. Biophys. Res. Commun. 424, 221\u2013227 (2012).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"78817_CR19","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.4049\/jimmunol.150.7.2920","volume":"150","author":"LS Schlesinger","year":"1993","unstructured":"Schlesinger, L. S. Macrophage phagocytosis of virulent but not attenuated strains of Mycobacterium tuberculosis is mediated by mannose receptors in addition to complement receptors. J. Immunol. 150, 2920\u20132930 (1993).","journal-title":"J. Immunol."},{"key":"78817_CR20","doi-asserted-by":"publisher","first-page":"17066","DOI":"10.1038\/s41598-018-35151-7","volume":"8","author":"S Zhang","year":"2018","unstructured":"Zhang, S., Shrestha, C. L. & Kopp, B. T. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function. Sci. Rep. 8, 17066 (2018).","journal-title":"Sci. Rep."},{"key":"78817_CR21","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1128\/JCM.38.2.910-913.2000","volume":"38","author":"E Mahenthiralingam","year":"2000","unstructured":"Mahenthiralingam, E. et al. Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex. J. Clin. Microbiol. 38, 910\u2013913 (2000).","journal-title":"J. Clin. Microbiol."},{"key":"78817_CR22","doi-asserted-by":"publisher","first-page":"e0186169","DOI":"10.1371\/journal.pone.0186169","volume":"12","author":"CL Shrestha","year":"2017","unstructured":"Shrestha, C. L. et al. Cysteamine-mediated clearance of antibiotic-resistant pathogens in human cystic fibrosis macrophages. PLoS ONE 12, e0186169 (2017).","journal-title":"PLoS ONE"},{"key":"78817_CR23","doi-asserted-by":"crossref","unstructured":"Assani, K., Shrestha, C.L., Rinehardt, H., Zhang, S., Robledo-Avila, F., Wellmerling, J. et al. AR-13 reduces antibiotic-resistant bacterial burden in cystic fibrosis phagocytes and improves cystic fibrosis transmembrane conductance regulator function. J. Cyst. Fibros. (2018).","DOI":"10.1016\/j.jcf.2018.10.010"},{"key":"78817_CR24","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.3389\/fimmu.2020.01871","volume":"11","author":"S Zhang","year":"2020","unstructured":"Zhang, S. et al. Consequences of CRISPR-Cas9-mediated CFTR knockout in human macrophages. Front. Immunol. 11, 1871 (2020).","journal-title":"Front. Immunol."},{"key":"78817_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4161\/cbt.4.1.1474","volume":"4","author":"BP Nutley","year":"2005","unstructured":"Nutley, B. P. et al. Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse. Mol. Cancer Ther. 4, 125\u2013139 (2005).","journal-title":"Mol. Cancer Ther."},{"key":"78817_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejps.2005.02.001","volume":"25","author":"M Vita","year":"2005","unstructured":"Vita, M. et al. Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat. Eur. J. Pharmaceut. Sci. 25, 91\u2013103 (2005).","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"78817_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3\u201326 (2001).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"78817_CR28","first-page":"CD013079","volume":"6","author":"F Frost","year":"2019","unstructured":"Frost, F., Shaw, M. & Nazareth, D. Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis. Cochrane Database Syst. Rev. 6, CD013079 (2019).","journal-title":"Cochrane Database Syst. Rev."},{"key":"78817_CR29","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1016\/j.ajic.2013.01.024","volume":"41","author":"S Lee","year":"2013","unstructured":"Lee, S. et al. An outbreak of Burkholderia cenocepacia associated with contaminated chlorhexidine solutions prepared in the hospital. Am. J. Infect. Control. 41, e93\u2013e96 (2013).","journal-title":"Am. J. Infect. Control."},{"key":"78817_CR30","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.ajic.2010.12.005","volume":"39","author":"CA Lucero","year":"2011","unstructured":"Lucero, C. A. et al. Outbreak of Burkholderia cepacia complex among ventilated pediatric patients linked to hospital sinks. Am. J. Infect. Control. 39, 775\u2013778 (2011).","journal-title":"Am. J. Infect. Control."},{"key":"78817_CR31","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","volume":"379","author":"D Keating","year":"2018","unstructured":"Keating, D. et al. VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N. Engl. J. Med. 379, 1612\u20131620 (2018).","journal-title":"N. Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78817-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78817-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78817-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T22:48:31Z","timestamp":1697323711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78817-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,10]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["78817"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-78817-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,10]]},"assertion":[{"value":"22 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BTK has previously served on a Vertex clinical CF advisory board. JE and LM are employed by ManRos Therapeutics. All other authors have no conflicts.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21700"}}